BioSpace News Archive

Arbutus Biopharma Corporation announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10 - 13, 2022.

Olema Pharmaceuticals, Inc. announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET (2:15 p.m. PT).

Vera Therapeutics, Inc. will present and participate in one-on-one investor meetings at the 40th Annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.

Relay Therapeutics, Inc. today provided an update for two of its ongoing first-in-human trials, RLY-2608, the first known allosteric, pan-mutant and isoform-selective PI3Kα inhibitor in clinical development, and RLY-4008, a highly selective, irreversible and oral small molecule inhibitor of FGFR2.

Catalyst Pharmaceuticals, Inc. announced that Patrick J. McEnany, Catalyst’s Chairman and Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will participate in two upcoming investor conferences.

Revolution Medicines, Inc. today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 40th Annual J.P. Morgan Healthcare Conference.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), today announced the completion of its Phase 1 clinical trial of 18-MC, the Company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder.

Stealth BioTherapeutics Corp announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, 2022.

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that dusquetide is effective at reducing tumor size in nonclinical xenograft models.